(Q37507532)

20 August 2017

1 reference

title

Diagnosis of urothelial carcinoma from urine (English)

1 reference

20 August 2017

0 references

Bernard Têtu

1

1 reference

20 August 2017

publication date

1 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

22 Suppl 2

1 reference

20 August 2017

page(s)

S53-9

1 reference

Prognostic markers in bladder cancer: a contemporary review of the literature

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Current bladder tumor tests: does their projected utility fulfill clinical necessity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Urine markers for bladder cancer surveillance: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Molecular markers in bladder cancer: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Current status of urinary cytology in the evaluation of bladder neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Guidelines for development of diagnostic markers in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Effect of intravesical instillation on performance of uCYT+ test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Detection of bladder cancer from the urine using fluorescence in situ hybridization technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Bladder cancer detection using FISH (UroVysion assay).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Immunocytology in the assessment of patients with asymptomatic hematuria

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Improved detection of recurrent bladder cancer using the Bard BTA stat Test

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Usefulness of the BTA STAT Test for the diagnosis of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Comparison of the Bard Trak test with voided urine cytology in the diagnosis and follow-up of bladder tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Comparison of screening methods in the detection of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Comparison of cytology and nuclear matrix protein 22 for the detection and follow-up of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Surveillance for recurrent bladder cancer using a point-of-care proteomic assay

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Role of uCyt+ in the detection and surveillance of urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Use of urinary biomarkers for bladder cancer surveillance: patient perspectives

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

Immunocytology in the assessment of patients with asymptomatic microhaematuria

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.193

7 January 2021

10.1038/MODPATHOL.2008.193

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

1042601199

0 references

Fatcat ID

release_vh2cr4wqqrfztfp3lkngm7mm5e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vh2cr4wqqrfztfp3lkngm7mm5e

24 November 2022

mapped directly with Wikidata item

1 reference